Class Central is learner-supported. When you buy through links on our site, we may earn an affiliate commission.

Dartmouth College

AXL: Advanced Opioid Use Disorder X-waiver Team Learning Collaborative MAT and Telemedicine

Dartmouth College via Independent


Dartmouth Health Continuing Education for Professionals Home, AXL: Advanced Opioid Use Disorder X-waiver Team Learning Collaborative MAT and Telemedicine, 9/1/2021 8:00:00 AM - 9/1/2024 9:00:00 AM, This series is designed to increase treatment capacity for opioid use disorders by training more prescribers to be able to treat substance or opioid use disorders.

Content includes:

Methadone & COVID 19
  • COVID 19 Hub Modifications
  • Methadone Tele-dosing
Buprenorphine Telemedicine
  • Benefits and Risks
  • Intakes: Clinical & Legal Procedures
  • Follow-up Assessment Procedures
  • Drug Testing Options
  • Platforms for Telemedicine
  • Modifications for COVID 19
Counseling Telemedicine
  • Psychotherapy: ind; group, case mgmt.
  • Ethical considerations and best practices
  • Online recovery supports for Patients
  • Online Resources for Professionals
  • Modifications for COVID 19

Frederick Hesse, MD
is an American Society of Addiction Medicine board-certified physician and Medical Director at Bradford Psychiatric Associates in Rutland and White River Junction, a spoke provider of MAT services with buprenorphine/naloxone, buprenorphine extended-release, and extended-release naltrexone. He has over 30 years of experience in treating substance use disorders including serving as medical director at Arms Acres and Conifer Park inpatient addiction rehabilitation facilities in New York state as well as acting medical director at Valley Vista inpatient addiction treatment program. In order to serve MAT patients in both western and eastern Vermont, Dr. Hesse began years ago to offer buprenorphine treatment via telemedicine.

Kate Burkholder, LADC/LCMHC is a spoke psychotherapist at Central Vermont Medical Center and Treatment Associates. She began providing telemedicine psychotherapy long before the outbreak of COVID 19 and has experience providing individual and group psychotherapy via telemedicine as well as telehealth case management, support, and facilitation of online peer recovery.

John Brooklyn, MD pioneered both methadone and buprenorphine treatments for Opioid Use Disorder in Vermont in the early 2000s and has been instrumental to the conception and development of the hub and spoke system. He is an Associate Clinical Professor of Family Medicine & Psychiatry at the Larner College of Medicine at UVM and is the medical director at both the Howard Center & BAART St. Albans hubs and serves as a staff physician at the Community Health Centers of Burlington. He continues to be involved with the UVM Dept of Psychiatry grants for educating medical students and community providers and research into novel ways of delivering buprenorphine. From 2016 to the present, Dr. Brooklyn has conducted a trial using Video Directly Observed Therapy for methadone and buprenorphine tele-dosing to reduce the demands of on-site dosing on patients.

Learning Outcome(s)
Participants will be able to identify at least three evidence-based strategies that are designed to enhance the clinical team-based care of patients with substance or opioid use disorders treatment.

The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**. 

* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).

** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Bibliographic Resources

Brooklyn J. Wheels and Waves: Reducing Barriers to Opioid Treatment. In. National Council for Mental Wellbeing NatCon19 Conference 2019:
Weiss-Tisman H. Regional Hospitals Explore Telehealth Options To Improve Health Care Access. Vermont Public Radio 2019; Accessed May 24, 2021.
Hilty DM, Ferrer DC, Parish MB, Johnston B, Callahan EJ, Yellowlees PM. The effectiveness of telemental health: a 2013 review. Telemed J E Health. 2013;19(6):444-454.
Volkow ND. Collision of the COVID-19 and Addiction Epidemics. Ann Intern Med. 2020;173(1):61-62.
U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet): Percentage of Visits for ILI by Age Group Reported by A Subset of ILINet Providers September 29, 2019 – April 4, 2020 Data as of April 9, 2020. Centers for Disease Control and Prevention (CDC); 2020. Accessed May 24, 2021.
Update on Telehealth Restrictions in Response to COVID-19. American Psychiatric Association; 2020. Accessed April 8 2020.
National Telehealth Technology Assessment Resource Center Clinician’s Guide to Video Platforms. 2020; Accessed May 24, 2021.
National Consortium of Telehealth Resource Centers. HIPPA & Telehealth A Stepwise Guide to Compliance. 2020; Accessed May 24, 2021.
National Consortium of Telehealth Resource Centers. HTRC Telehealth Etiquette Checklist. 2020; Accessed May 24, 2021.
Boulanger S. Top 5-Group via Telebehavioral Health. Telehealth Learning Series 2020; Accessed May 24, 2021.
American Telemedicine Association Resources. Accessed May 24, 2021.
Substance Abuse and Mental Health Services Administration Considerations for the Care and Treatment of Mental and Substance Use Disorders in the COVID-19 Epidemic: March 20, 2020. 2020; Accessed May 24, 2021.


Start your review of AXL: Advanced Opioid Use Disorder X-waiver Team Learning Collaborative MAT and Telemedicine

Never Stop Learning.

Get personalized course recommendations, track subjects and courses with reminders, and more.

Someone learning on their laptop while sitting on the floor.